A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors

• Status: Unknown status
• Trial end date: 2019-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This Phase 1a, single center, open-label, repeat dose study will evaluate the safety, efficacy, and Pharmacokinetics of ascending doses of OBP-801 in patients with advanced solid tumors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Oncolys BioPharma Inc

Criteria

Patient Inclusion Criteria

Patients must meet all of the following inclusion criteria to be eligible for enrollment into the study:

• Histologically or cytologically confirmed metastatic or unresectable solid tumor.

• Has failed treatment with all standard therapies for their malignancy.

• Adequate Karnofsky Performance Status.

• An expected survival of at least 3 months.

• Adequate organ and bone marrow function.

• Signed informed consent form for study participation prior to screening.

Patient Exclusion Criteria

Patients presenting with any of the following will be excluded in the study:

• Clinically significant disease as defined by the protocol.

• Surgical therapy or other therapies within period as defined by the protocol.

• Any condition that will interfere with compliance with the protocol as determined by investigator.